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Splenomegaly and secondary hypersplenism may be associ- 
ated with acute and chronic infections, autoimmune states, 
portal hypertension or splenic vein thrombosis, and a 
number of infiltrative and neoplastic conditions involving 
the spleen. Our experience and that of others with these 
various conditions demonstrates that the decision to per- 
form splenectomy should be based on well-defined and 
often strictly limited indications. Except for idiopathic 
splenomegaly, the presence and severity of secondary 
hypersplenism or severely symptomatic splenomegaly 
should be well documented. In each case, the potential for 
palliation and known mean duration of expected response 
must be weighed against the increased morbidity and 
mortality of splenectomy (as compared to operation for 
"primary" hypersplenism). 
Hypersplenism is a nonspecific term indicating that 
the spleen may be functioning in a manner having a 
deleterious effect on the blood cells of the host. The 
usual criteria utilized to indicate the presence of this 
condition are: (a) splenomegaly; (b) a clinically 
significant decrease in one or more of the cellular 
elements of the blood; (c) the presence of a normal 
or hypercellular bone marrow; and (d) correction or 
improvement of the cytopenia by splenectomy. 
However,  in clinical application, all of these ele- 
ments may not be satisfied. Splenomegaly is not and 
should not be present in idiopathic thrombocy- 
topenic purpura. A cytopenia present in several of 
the myeloproliferative disorders may respond to 
splenectomy in spite of the presence of decreased 
cellular precursors in the bone marrow. 
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The separation of hypersplenism into primary 
and secondary categories is also imprecise. The 
diseases usually included under "primary" hyper- 
splenism are those in which the fundamental defect 
is thought to be related to a congenital or acquired 
alteration in cell membrane or structure of 
hematopoietic cells (idiopathic thrombocytopenic 
purpura, acquired hemolytic anemia, some of the 
congenital hemolytic anemias, etc.). 
This discussion will be confined to selected enti- 
ties usually considered to be associated with "sec- 
ondary" hypersplenism in which splenomegaly and 
altered splenic microcirculation may bring about 
splenic sequestration of erythrocytes, neutrophils, 
or platelets. Here, again, the specificity of this 
terminology is debatable since, in several second- 
ary hypersplenic conditions (Felty's syndrome, 
hairy cell leukemia), altered cell structure may also 
play a role in the pathophysiologic mechanism of 
cytopenia. 
Secondary hypersplenism has been associated 
with certain acute and chronic infections, autoim- 
mune states (Felty's syndrome, systemic lupus 
erythematosus), infiltrative and neoplastic condi- 
tions involving the spleen (sarcoidosis, Gaucher's 
disease, several myeloproliferative disorders, and 
lymphomas) and occasionally with "congestive 
splenomegaly" brought about by portal hyperten- 
sion or splenic vein thrombosis. 
Leukemia  
Splenectomy has been performed for several types 
of leukemia for more than 100 years, but its value 
and limitations have only been defined in the past 
few years. 
Only in the relatively rare hairy cell leukemia is 
splenectomy the initial treatment of choice. Al- 
though this condition was recognized as a distinct 
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entity more than 25 years ago, in the past 10 years 
other related conditions have been appropriately 
excluded as a result of a better definition of marrow 
and splenic pathological findings and utilization of 
the tartrate-resistant acid phosphatase stain which 
is positive in 85-90% of cases. This usually slowly 
progressive disease is probably a variant form of 
chronic lymphocytic leukemia since the cell of 
origin appears to be a transformed lymphocyte. 
Median survival after diagnosis is 3-4 years, but 
many patients live for 8-10 years or longer. Re- 
sponses to intensive chemotherapy or to cortico- 
steroids have been poor. Splenectomy is indicated 
if the patient develops a hypersplenic complication 
such as severe anemia, thrombocytopenia, or 
granulocytopenia. In our experience with 17 pa- 
tients followed at our institution during the past 10 
years [1], 16 have had a splenectomy for one of 
these indications. There have been no operative 
deaths and only 1 postoperative superficial wound 
infection. Nine of the 16 splenectomized patients 
are still alive with a median postoperative survival 
of more than 42 months. Only 2 patients have 
required postoperative chemotherapy with low- 
dose chlorambucil. Thirteen of 16 have achieved a 
satisfactory hematologic response (hematocrit: 35 
vol % or above; granulocytes: 1,000/mm 3 or more; 
platelets: 100,000/mm 3 or greater) after operation. 
In a recent analysis of 391 cases [2], patients who 
had a splenectomy survived longer than patients 
who did not undergo surgery; operative mortality 
rate was 2%. About 80% of patients still achieve an 
"acceptable hematologic response" (as previously 
defined) [2]. In patients who fail to achieve an 
adequate response to splenectomy, low-dose 
chlorambucil (4 mg/day) has been of value [3]. 
Recently, bone marrow transplantation [4] or daily 
administration of alpha interferon [5] have been 
proposed as additional therapeutic modalities. 
While many patients with chronic lymphocytic 
leukemia live for 5-10 years with little or no treat- 
ment, a small fraction may develop hypersplenic 
complications or massive symptomatic splenomeg- 
aly, usually relatively late in the course of this 
disease. Of our 15 patients operated on for one of 
these indications [1], 2 died after operation from 
persistent thrombocytopenic bleeding. Four pa- 
tients with hemolytic anemia, 1 with pancytopenia, 
and 4 with symptomatic splenomegaly had excellent 
responses to operation with a mean survival of 
greater than 4 years. Of 6 patients with thrombo- 
cytopenia, only 2 achieved a satisfactory rise in 
platelet count. Others have reported similar results 
[6, 7]. 
The utilization of splenectomy in the manage- 
ment of chronic granulocytic leukemia (CGL) has 
been much more controversial. In our hospital, the 
operation has been performed primarily for acute 
symptoms and fear of splenic rupture, severe 
thrombocytopenia, or highly symptomatic spleno- 
megaly [1]. Of 11 patients, 8 were operated on in the 
"accelerated phase" of their disease [8] in which 
median survival is only 3-6 months. Three died 
postoperatively. In 2 patients splenectomy was per- 
formed as a preliminary to bone marrow transplan- 
tation and both are alive (at 1 and 3 years, respec- 
tively). Many reports attributing value to splenec- 
tomy for this condition have been anecdotal. How- 
ever, several recent nonrandomized comparisons of 
operation versus no operation early in the chronic 
phase of CGL have shown that splenectomy does 
not delay progression from the chronic to the blastic 
phase and does not prolong survival [9, 10]. In a 
recent prospective trial, similar conclusions were 
reached [11]. 
Stage IV Lymphoma 
On rare occasions, patients with far-advanced 
Hodgkin's disease or non-Hodgkin's lymphoma will 
develop severe hypersplenism which is refractory 
to chemotherapy, or a cytopenia interferes with 
administration of adequate doses of chemothera- 
peutic agents. In our experience with 5 such pa- 
tients, 1 died 3 weeks postoperatively with pneu- 
monia. The other 4 achieved a very satisfactory 
cytologic response with survival from 5 months to 
more than 8 years. The entire spectrum of 
cytopenias were encountered: thrombocytopenia in 
1 patient, hemolytic anemia in 1, hemolytic anemia 
and thrombocytopenia in another, and pancyto- 
penia in the fourth. In 3 patients a sustained remis- 
sion of hypersplenism was achieved until death 
from lymphoma. The fourth and longest surviving 
patient had a relapse of a Coombs'-positive hemo- 
lytic anemia 2 years after operation which re- 
sponded to steroid therapy and then remained in 
remission until a terminal relapse 81/2 years after 
splenectomy. 
Sarcoidosis 
Although 6% of patients with sarcoidosis are said to 
have splenomegaly [12], the need for splenectomy 
is extremely uncommon. In the largest reported 
series, splenectomy was performed for sympto- 
matic splenomegaly in 7 patients, for infarction or 
rupture in 2, for hypersplenism in 5 (all of whom 
responded), and for other indications in 2 [13]. In 
our personal experience with 8 patients, diagnosis 
was the indication in 4 individuals who had no prior 
diagnosis and manifestations compatible with pos- 
sible lymphoma (fever of undetermined origin, 
W.W. Coon: Splenectomy for Splenomegaly 439 
splenomegaly, para-aortic lymphadenopathy, etc.). 
One patient had symptomatic splenomegaly. In the 
other 3 patients, surgery was performed for hemo- 
lytic anemia or neutropenia and all achieved remis- 
sion after splenectomy. 
Agnogenic Myeloid Metaplasia (AMM) 
Selected patients with this myeloproliferative dis- 
order may obtain palliative benefit from splenec- 
tomy, but operative morbidity and mortality rates 
are appreciable and it is doubtful whether removal 
of the spleen affects prognosis [14]. Diagnosis is 
based on the presence of splenomegaly and im- 
mature myeloid and erythroid cells in peripheral 
blood, anisocytosis and poikilocytosis, and variable 
degrees of fibrosis in bone marrow. For determina- 
tion of prognosis and decisions regarding operative 
benefit, patients with "primary" AMM should be 
distinguished from those in whom AMM evolves 
following treatment for polycythemia rubra vera or 
essential thrombocythemia. 
Our operative experience with this condition in- 
cludes 34 patients between the ages of 40 and 76 
years, 27 of whom had primary AMM. Splenectomy 
was performed for hypersplenism in 20 individuals, 
for symptomatic splenomegaly in 11, in association 
with other operations in 2, and for traumatic rupture 
in 1 patient. The postoperative hematologic re- 
sponse could not be evaluated in 6 patients with 
hypersptenism because of postoperative death, 
persistent chronic gastrointestinal bleeding, or 
myelosuppressive chemotherapy. In 10 patients 
with chronic anemia and decreased erythrocyte 
survival, 8 had a postoperative increase in the 
hematocrit reading of 5 vol % or more which was 
maintained for periods of 6 months to more than 8 
years. A sustained increase in platelet count (for 
more than 1 year) was observed in 3 of 4 thrombo- 
cytopenic patients. 
Symptomatic splenomegaly is manifested by 
chronic left upper quadrant abdominal and back 
pain and early satiety (from gastric displacement). 
Splenic weight in this group ranged from 980 to 
4,200 g. All survivors obtained significant sympto- 
matic benefit. 
Four postoperative deaths resulted from leuke- 
mic conversion, gastrointestinal bleeding, acute he- 
patic necrosis, or sepsis, and morbidity from bleed- 
ing or sepsis was encountered in 12 patients. Mean 
duration of survival following splenectomy was 22 
months for men and 46 months for women with 
primary AMM but only 8 months for secondary 
AMM. The majority of late deaths were due to 
leukemic conversion or to gastrointestinal bleeding. 
Since morbidity and mortality are considerable 
and survival is limited after splenectomy, careful 
selection of patients and intensive preoperative 
preparation are essential. Our experience with a 
very short postoperative survival in subjects with 
secondary AMM indicates that surgery in this sub- 
group is of questionable benefit. In patients with 
chronic anemia requiring frequent transfusion, a 
source of continued gastrointestinal blood toss 
should be eliminated. Determination of 51Cr- 
erythrocyte survival may help separate those pa- 
tients with hypersplenic pooling and sequestration 
from those with marrow production failure. Five to 
ten percent of patients with myeloid metaplasia will 
have secondary portal hypertension [15], but an 
adjunctive splenorenal shunt is seldom indicated; 
Schwartz [16] has reported that in 6 patients with 
AMM and increased portal pressures, splenectomy 
resulted in a decrease in portal pressures to normal 
or near normal in all. Preoperative assessment of 
coagulation profile and platelet function is impor- 
tant because much of the immediate morbidity is 
related to thrombotic and hemorrhagic complica- 
tions. Qualitative platelet abnormalities are fre- 
quently demonstrable in patients with myelopro- 
liferative disorders, and, if present, platelet trans- 
fusion during operation may be helpful. In addition, 
Silverstein and Remine [15] have found laboratory 
evidence of subclinical disseminated intravascular 
coagulation (decreased platelets and factors V and 
VIII and increased fibrin degradation products) in 
12% of these patients and advise against surgery in 
this circumstance. 
We now restrict splenectomy in this condition to 
patients with primary myeloid metaplasia and 
hypersplenic anemia or thrombocytopenia or symp- 
tomatic splenomegaly whose preoperative assess- 
ment indicates an acceptable operative risk. 
Felty's Syndrome 
This entity is characterized by splenic neutropenia 
(total white blood cell count less than 3,500/ram 3 
and neutrophil count less than 2,000/ram 3) develop- 
ing in a patient with rheumatoid arthritis and usually 
accompanied by splenomegaly and anemia and oc- 
casionally by cutaneous ulcers of the leg. There has 
been considerable debate in recent years concern- 
ing the value of splenectomy in preventing episodes 
of infection. Since only approximately 1 in 300 
patients with rheumatoid arthritis develop this syn- 
drome [17], no prospective trials have been con- 
ducted. Many physicians have tried to manage 
problems of sepsis with antibiotic therapy alone or 
in combination with administration of lithium in an 
attempt to stimulate granulopoietic precursors in 
the bone marrow. In our recent nonrandomized 
assessment of 20 evaluable patients receiving 
nonoperative management and 20 splenectomized 
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patients [18], we have attempted to refine possible 
criteria for operation. 
Among the 20 subjects not undergoing surgery, 
16 presented with an infection and/or a leg ulcer. 
There have been 2 deaths from sepsis and 1 episode 
of severe pneumonia. Leg ulcers persisted in 5 of 6 
patients, healing in 1 after a 7-year period of obser- 
vation. Of 5 patients given a trial of lithium in doses 
of 900 to 1,800 mg/day, only 1 achieved a satisfac- 
tory granulocytic response. 
Of the 20 splenectomized patients, 4 were lost to 
follow-up after hospital discharge, 2 having 
achieved a satisfactory neutrophil response to 
greater than 2,000/ram 3. There was no operative 
mortality. In the remaining 16 patients who have 
been observed for 6 months to 20 years (mean: 4 
years), 13 have had a prompt and sustained 
leukocyte (above 3,500) and neutrophil response 
(above 2,000). None have had further infections. Of 
the 3 patients with follow-up who were splenectomy 
"failures" (unsatisfactory cytologic response), 1 
died of sepsis 5 years later and a second has had an 
episode of pharyngitis responsive to antibiotics. Of 
5 patients with leg ulcers, 3 have healed; 1 patient 
was lost to follow-up. No clinical or laboratory 
criteria have been found that can predict response 
to splenectomy. In patients who had a satisfactory 
neutrophil response to splenectomy or who had a 
remission during nonoperative management, ane- 
mia also improved. The infections that appeared 
after splenectomy occurred in patients with an 
inadequate neutrophil response. Other authors have 
also reported correction of neutropenia and relief 
from recurrent infection in 60-80% of patients un- 
dergoing splenectomy [17, 19, 20]. 
Our data on the natural history of Felty's syn- 
drome in patients not undergoing surgery lead us to 
believe that, with rare exceptions, hematologic ab- 
normalities alone are not a sufficient indication for 
operation unless the patient has an associated se- 
vere hemolytic anemia or thrombocytopenia. Al- 
though neutropenia of fewer than 500 cells/mm 3 has 
been proposed as an indication for operation, we 
found no correlation between lowest neutrophil 
count and the development, severity, or frequency 
of infection. On the other hand, after the appear- 
ance of serious or recurrent infection, splenectomy 
appears to be of value regardless of the severity of 
the neutropenia. Although our sample is small, the 
likelihood of healing of a leg ulcer seems improved 
after splenectomy. 
"Congestive Splenomegaly" 
This nonspecific term includes a spectrum of condi- 
tions of varying etiology and severity. At one end of 
the spectrum is Banti's syndrome in a patient with 
frank cirrhosis, portal hypertension, and spleno- 
megaly with or without clinically significant 
hypersplenism. At the other end is the individual 
with idiopathic splenomegaly and/or hypersplenism 
in whom, after splenectomy, the pathologist de- 
scribes "congestion" of the spleen but no obvious 
liver disease or extrahepatic portal or splenic ve- 
nous obstruction is demonstrable. Between these 
extremes are many patients with parasitic, "infiltra- 
tive" (sarcoidosis, amyloidosis), and myeloprolif- 
erative disorders in whom variable degrees of 
intrahepatic or extrahepatic portal venous obstruc- 
tion may play a pathogenic role in the development 
of splenomegaly and hypersplenism. 
Splenectomy is the treatment of choice in pa- 
tients with splenic vein thrombosis, "left-sided por- 
tal hypertension," and bleeding esophageal varices. 
The indication for operation is almost always re- 
lated to the presence of esophageal varices rather 
than clinically significant hypersplenism. Although 
chronic pancreatitis is the most frequent underlying 
cause of isolated splenic vein thrombosis, one 
should be aware that previously undiagnosed pan- 
creatic carcinoma or lymphoma can also produce 
this condition. 
Most surgeons would now agree that splenec- 
tomy alone is inappropriate in patients with hepatic 
cirrhosis, portal hypertension, bleeding esophageal 
varices, and signs of hypersplenism. Warren and 
associates [21] have recently reported that platelet 
counts less than 50,000/mm 3 were found in 8-10% of 
their patients presenting with variceal bleeding; 
thrombocytopenia was observed more frequently in 
patients with nonalcoholic as compared to those 
with alcoholic liver disease. Boivin [22] observed a 
lower frequency of thrombocytopenia in patients 
with cirrhosis (7 of 185 cases with platelets less than 
50,000/mm3). In his experience the level of 
thrombocytopenia present in these individuals did 
not affect mortality or morbidity after operations for 
portal decompression. While most of the currently 
utilized shunt procedures for management of portal 
hypertension leave the spleen intact, the majority of 
patients with associated thrombocytopenia will re- 
spond with an increase in platelet count postopera- 
tively, but in some, the rise may not be sustained 
[23] and the increase in platelets (or leukocytes) will 
not reach normal values [24]. Splenectomy should 
be reserved for the very rare patient with severe 
residual thrombocytopenia after shunt. 
In our experience with idiopathic splenomegaly 
and hypersplenism [25], we have encountered 3 
patients in whom the diagnosis of relatively mild 
cirrhosis was made only at the time of splenecto- 
my and liver biopsy. Thrombocytopenia (platelet 
counts: 38 to 68,000) improved after splenectomy, 
W.W. Coon: Splenectomy for Splenomegaly 441 
and platelet counts have remained normal for peri- 
ods of follow-up of 1 to 8 years. In 4 other patients 
with idiopathic neutropenia (2 with associated 
thrombocytopenia), the only histologic finding was 
"splenic congestion" without evidence of liver dis- 
ease. All achieved a satisfactory cytologic response 
to splenectomy. 
Portal hypertension secondary to either 
extrahepatic or intrahepatic portal obstruction in 
patients with hypersplenism associated with 
myeloproliferative disorders [26] may add to mor- 
bidity and mortality. As mentioned in prior discus- 
sion, many of these patients achieve little or only 
very short-term benefit from an operation and, as 
Schwartz [16] has shown, adjunctive shunt proce- 
dures are seldom indicated. However, awareness of 
the possible presence of portal hypertension, and 
also platelet and coagulative abnormalities [15] in 
patients with these conditions is important because 
some of these individuals will require urgent opera- 
tions for other problems. As Wasserman and 
Gilbert [27] have reported for patients with polycy- 
themia vera (and it is equally true in other 
myeloproliferative conditions), any abdominal op- 
eration is associated with an appreciable mortality 
and morbidity from hemorrhage or thrombosis. 
Gaucher's Disease and Other Reticuloendothelioses 
The benefit of splenectomy in these conditions is 
chiefly in selected patients with Gaucher's disease. 
This hereditofamilial deficiency of acid-beta-gluco- 
sidase results in progressive accumulation of gluco- 
sylceramide in the spleen, bringing about massive 
splenomegaly and frequently secondary hypersplen- 
ism. Since this is a disease of the Jewish population, 
primarily Ashkenazi Jews, the greatest experience 
has been accumulated in Israel and in Jewish hos- 
pitals in other countries. Matoth and Fried [28] have 
reported 16 splenectomies without mortality in pa- 
tients of ages 5 to 47 years; splenectomy was 
performed principally for thrombocytopenia with a 
prompt increase in platelets which is usually main- 
tained for years. The effect on anemia is less 
dramatic. Similar results have been obtained in 
several other small series of patients [29, 30]. Our 
limited experience with 3 patients is similar. All had 
a prompt and sustained remission of thrombocy- 
topenia. An associated anemia in a 4-year-old fe- 
male also improved. Although there has been some 
concern that splenectomy may worsen the clinical 
course and accelerate the progression of orthopedic 
problems, others feel that this impression is errone- 
ous because the more severely affected young pa- 
tients are the ones who have early splenectomy and 
are more likely to develop later orthopedic prob- 
lems [31]. 
In the past, splenectomy has been performed in a 
few patients with Niemann-Pick disease, but 
follow-up of these subjects with a very limited 
prognosis has demonstrated no alteration in sur- 
vival, although anemia improved moderately in 
several [32]. 
Tropical Splenomegaly Syndrome 
This condition, recognized in Africa and New 
Guinea for many years, is seen in patients with high 
titers of antimalarial antibodies and is associated 
with lymphocytosis in the bone marrow, anemia 
and occasionally mild leukopenia and thrombocy- 
topenia, reactive macroglobulinemia, increased 
IgM levels, and reduced serum complement (C3) 
[33]. A causal relationship to malaria has not been 
established. Splenectomy has been shown to im- 
prove the cytopenias [34, 35]. Many patients will 
respond to prolonged antimalarial therapy [36]; 
splenectomy is now reserved for those patients in 
whom anemia fails to respond to antimalarial drugs 
and those with symptomatic splenomegaly (chronic 
abdominal pain) [34]. 
Idiopathic Splenomegaly and Hypersplenism 
A mrlange of "idiopathic" conditions have been 
described over the past 40 years. Wiseman and 
Doan [37] classified a group of patients with 
splenomegaly and neutropenia without specific 
splenic histology as "primary splenic neutropenia." 
More recently, Dacie and associates [38, 39] have 
followed these patients with "non-tropical idio- 
pathic splenomegaly" and hypersplenism in whom 
no diagnosis was made after splenectomy; 4 have 
subsequently developed lymphoma. 
Our patients with idiopathic splenomegaly [25] 
have differed from those of Dacie and of other 
investigators [40, 41] but are similar to those of 
Goonewardene and co-workers [42]. Although 18 of 
28 patients with splenomegaly of undetermined ori- 
gin had some degree of hypersplenism (hematocrit 
< 30 vol %, leukocytes < 3,500/ram 3 or neutrophils 
< 2,000/mm 3 or platelets < 100,000/mm3), the 
cytopenias were usually mild; splenectomy was 
performed for detection of possible lymphoma. No 
lymphoma was found at the time of operation and 
only 1 patient has subsequently had this diagnosis 
made. Only 7 had a specific diagnosis made as a 
result of the operation (cirrhosis, splenic cyst, 
sarcoidosis). 
This experience with a group of patients who 
were relatively young (mean age: 28 years) has led 
us to be more conservative with respect to recom- 
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mending splenectomy, provided that no other mani- 
festations compatible with the diagnosis of 
lymphoma are present. Many who are young, 
asymptomatic, and with a history of recent infec- 
tion can be closely watched and a decision regard- 
ing splenectomy deferred. 
R 6 u m 6  
La spl6nom6galie avec hyperspl6nisme secondaire 
rel6ve de multiples causes: infection aigue ou 
chronique, 6tats autoimmunologiques, hyperten- 
sion portale, thrombose de la veine spl6nique, 
16sions tumorales spl6niques. L'exp6rience de 
l'auteur qui rejoint celle de nombreux coll6gues lui 
permet d'affirmer que les indications de la spl6- 
nectomie doivent ~tre bien d6finies et sont stricte- 
ment limit6es. A l'exception de la spl6nom6galie 
idiopathique, l'existence et l'intensit6 de 
l'hyperspl6nisme, l'importance des symptomes 
provoqu6s par la spl6nom6galie doivent 6tre 
aprr6ci6es avec pr6cision. Dans chaque cas le 
potentiel de la r6mission de l'affection et la dur6e de 
la r6mission doivent 6tre pris en consid6ration en 
fonction de l'6ventuelle morbidit6 et de l'6ventuelle 
mortalit6 de la spl6nectomie (par comparaison avec 
la spl6nectomie pour hyperspl6nisme primaire). 
R e s u m e n  
Eplenomegalia e hiperesplenismo secundario 
pueden estar asociados con infecciones agudas y 
cr6nicas, estados autoinmunes (sfndrome de Felty, 
lupus eritematoso sist6mico), "esplenomegalia con- 
gestiva" por hipertensi6n portal o trombosis de la 
vena espl6nica y con una variedad de entidades de 
tipo infiltrativo y neoplfisico que afectan al bazo 
(sarcoidosis, enfermedad de Gaucher, varios 
des6rdenes mieloproliferativos y linfomas). 
Nuestra experiencia, y aquella de otros autores, 
con tales condiciones demuestra que la decisi6n de 
realizar esplenectomfa debe estar fundamentada en 
indicaciones bien definidas y estrictamente limita- 
das. Excepto en casos de esplenomegalia idio- 
p~tica, la presencia y severidad del hiperesplenismo 
secundario o de esplenomegalia severamente sinto- 
m~itica debe ser bien documentada. En cada caso 
debe determinarse el potencial de paliaci6n y la 
duraci6n de la respuesta que se espera obtener 
frente a la incrementada morbilidad y mortalidad de 
la esplenectomia (en comparaci6n con la operaci6n 
que se realiza por hiperesplenismo "primario"). 
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